VeraMorph

VeraMorph is a specialty pharmaceutical company that has developed a proprietary, environmentally-responsive oral drug delivery platform known as DPOD (Dissociated Polymeric Oral Dosages). This technology utilizes a unique mechanism of action where a cross-linked hydrogel structure transforms into individual polymers that are released alongside drug nanoparticles. By improving the solubility and stabilization of poorly soluble drug substances without chemical modification, the platform aims to enhance the clinical efficacy and therapeutic potential of both novel compounds and existing approved medications. VeraMorph’s approach is designed to be highly compatible across a broad range of drug properties and is scalable for efficient development.

The company focuses on maximizing therapeutic efficacy and patient outcomes by developing a portfolio of clinically-differentiated oral versions of approved drugs and out-licensing its platform technology to pharmaceutical partners. A key application is the development of an oral formulation of fulvestrant for metastatic breast cancer, which seeks to replace the standard, painful monthly intramuscular injections with a more potent and convenient treatment. By streamlining formulation optimization and clinical translation, VeraMorph aims to reduce the significant time, financial, and clinical risks associated with traditional pharmaceutical R&D, ultimately working to improve the standard of care for various disease indications.